Business Wire

Abzena Announces 20m$ Investment into Expansion of Integrated Biotherapeutics Offering (Biologics Drug Substance and ADC) and Makes Key Executive Appointment

Jaa

Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 L scale biologics equipment with 20m$ of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego, which will be equipped with Sartorius single use bioreactors. Abzena’s existing expertise in cell line development is strengthened with a new ambr® 15 automateand high throughput bioreactor in Cambridge, UK, and existing synthetic chemistry capacity is increased with build out of a fully equipped multifume hood laboratory in Bristol, Pennsylvania.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181106005500/en/

Abzena's biomanufacturing facility in Lusk, San Diego where investment into two new manufacturing su ...

Abzena's biomanufacturing facility in Lusk, San Diego where investment into two new manufacturing suites at 500 L and 2000 L will take place. (Photo: Business Wire)

Dr. Goldman stated, “Sponsors have noted our unique single source high quality integrated solution for biotherapeutics and Antibody Drug Conjugates (ADC) ranging from discovery to phase II scale under GMP. They wish to maintain excellent scientific quality, have a single point of contact and avoid risks of tech transfer. We have received many requests to support programs to phase II and beyond. We will continue to deliver industry-leading drug discovery, development and manufacturing services from our world-class, fully-integrated sites in the US and UK.”

Dr. Goldman explained that Abzena’s antibody Drug Substance manufacturing solution will be built in two new suites housed in the facility recently opened by Abzena in San Diego. These will contain new Sartorius 500 L and 2000 L single use bioreactors supported by a comprehensive range of scale up and process development equipment. The service will be further complemented by additional cell line development and chemistry capacity.

“Our company is experiencing significant demand for biologics, ADC constructs and other complex small molecules [or APIs]. We are delighted to commit approximately 20m$ to initiate these improvements which will start to become available to customers during 2019.”

Dr. Goldman concluded, “We are also delighted to announce the addition of Richard Milbank as Chief Financial Officer. Richard brings a wealth of expertise including in senior financial roles in many sectors, including eight years as CFO at NextPharma, a leading Contract Drug Manufacturing Organization. He trained as a Chartered Accountant at Price Waterhouse and is a graduate of Hull University in the United Kingdom.”

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Abzena, visit  www.abzena.com

Contact information

Abzena
Joseph Reeds
joseph.reeds@abzena.com
+441223 903367

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

FLIR Introduces Assisted Docking Technology and First Boat Manufacturer Partner22.1.2019 12:00Tiedote

FLIR Systems, Inc. (NASDAQ: FLIR) today announced the Raymarine DockSense™ assisted docking system, the marine industry’s first intelligent object recognition and motion sensing assisted docking solution for recreational boating. DockSense system uses FLIR machine vision camera technology and video analytics to integrate intelligence gathered from surrounding imagery with the vessel’s propulsion and steering system to assist boat owners in tight quarter docking maneuvering. Additionally, FLIR announced that Prestige Yachts, a Groupe Beneteau brand, will become the first to demonstrate the technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005313/en/ Docking a boat can be a stressful experience, even for the most experienced captains. Often wind and tides make the task more difficult, and docking mishaps can become expensive repairs and safety hazards. The DockSense system is designed to augment a captain's boat

BIOCERES and UNION ACQUISITION CORP. announce Bioceres’ unaudited quarterly operating results for the period ended December 31, 201822.1.2019 11:52Tiedote

Bioceres, a leading Latin American agricultural biotech company (the “Company”), and Union Acquisition Corp. (NYSE: LTN) (“UAC”), a special purpose acquisition company, today announced the Company’s unaudited operating results for the quarter ended December 31, 2018. The parties had previously announced the execution of a definitive share exchange agreement (the “Exchange Agreement”) pursuant to which the Company will contribute its agricultural solutions business in exchange for equity of UAC. The Company reported unaudited revenues of $62.6 million during the quarter ended December 31, 2018, which represents a 33% growth rate over the same period a year ago. The adjustments and the translation mechanism from the application of IAS 29 had a positive impact of $8.7 million during the quarter ended December 31, 2018. Additionally, the Company’s management team expects Gross Profit and EBITDA margin performance to exceed that of the same period a year ago. Members of UAC’s sponsor and, o

Tradeshift Announces Record Year and Exceptional Growth in Every Category Heading Into 201922.1.2019 11:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the fourth quarter of 2018, marking the eleventh quarter in a row of successive growth and beating targets. Tradeshift’s fourth quarter growth stats announced today include: YoY new bookings grew 250 percent New total contract value grew by $59M in Q4 YoY revenue grew 178 percent (trailing 12 months) Gross Merchandise Volume (GMV) more than doubled, growing by 112 percent YoY Tradeshift Go experienced high growth with 12 deals signed in Q4 Signed App partner Transfermate, allowing Tradeshift customers to easily receive and make foreign currency payments Expanded Partner ecosystem with two additional BPO partners signed The company’s customer roster continued strong growth this quarter adding a record 49 new customers, including Charter Hall, HSBC, Econocom and more. “2018 was a record setting operational year for us,” said Christian Lanng, CEO and co-founder of Tradeshift. “It’s been so grati

Bridgestone Europe To Acquire TomTom Telematics For €910 Million Cash Consideration22.1.2019 09:58Tiedote

Bridgestone Europe NV/SA (“Bridgestone”), a subsidiary of Bridgestone Corporation in EMEA, has entered into an agreement with TomTom to acquire its telematics business, for a cash consideration of €910 million. The transaction will bring together the world’s largest tyre and rubber company with the number one provider of digital fleet solutions in Europe, creating a leading data platform for connected vehicles. TomTom Telematics will accelerate Bridgestone on its journey to becoming a mobility solutions leader in the region, and the combination of both companies’ offerings will allow Bridgestone to cross-sell tyres and solutions to a larger customer base. Furthermore, the data access will enhance Bridgestone’s virtual tyre development and testing as well as connected tyre innovation benefiting all customers including OEMs. New social, economic and technological megatrends are pushing the pace of change in the automotive industry and the future of vehicles is connected, autonomous, shar

GA Telesis Board Appoints Norman Liu as an Independent Director22.1.2019 09:00Tiedote

GA Telesis, LLC, a leading global commercial aviation integrated services provider, announces that its Board of Directors will appoint Norman C.T. Liu as an Independent Board Member effective February 1, 2019. Norm brings over 35 years of experience in aviation financing, infrastructure investing and investment banking. He is the former Chairman, President and CEO of GE Capital Aviation Services (“GECAS"), a world leader in commercial aircraft leasing and financing. He retired from GE at the end of 2016 after 30 years of service and is currently a senior advisor to various companies in the infrastructure and aviation sectors. He was an Advanced Leadership Fellow at Harvard in 2017 and also serves as an Adjunct Professor at University College Dublin in Ireland. He received his bachelor’s degree from Yale University and his MBA from Harvard Business School. “We are pleased that Norm will be joining our Board to participate in the explosive growth of our franchise,” said Abdol Moabery, Pr

Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients22.1.2019 09:00Tiedote

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005426/en/ Further to the announcement on 29 October 2018, Vifor Pharma provides an update to the results of the Proactive IV irOn Therapy in haemodiALysis patients (PIVOTAL) trial. This update was necessitated by identification of a programming error in the original analysis by the investigators. The re-analysis of the data revealed a statistically significant improvement in the treatment effects of a higher dose of Venofer® (i.v. iron sucrose) compared with a lower dose. These results supersede those presented at the High-Impact Clinical Trial session at ASN Kidney Week 2018 and published on The New England Journal of Medicine website, NEJM.org, on 26 October 2018. The updated results can be viewed on: www.NEJM.org (DOI: 10.1056/NEJMoa1810742). In the updated results, the primary endpoint ‒ which was the composite of nonfatal myocardial infarction, nonfa

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme